November 15, 2021

Includes Representatives from All 23 U.S. & Canadian Schools and Colleges of Optometry

SAN RAMON, Calif., Nov. 15, 2021—With 58% of North American residents expected to have myopia by 20501, CooperVision is committed to investing in the long-term growth of myopia management. In that spirt, the company has launched an initiative that will impact the eye care profession and patients for decades to come—the CooperVision Student Myopia Leadership Society.

Each of the 23 schools and colleges of optometry across the United States and Canada have designated a third-year student for participation, based on their interest in the disease, academic performance and other school-determined criteria. Selected students serve a one-year term.

Participants receive several opportunities to collaborate with their peers, hear from myopia management experts, improve their understanding of evidence-based science, and gain insights into successful practice operations. The students are also offered travel grants to two educational industry events of their choosing, including the American Academy of Optometry Annual Meeting, Global Specialty Lens Symposium, Vision by Design, and the Global Myopia Symposium.

In addition, the myopia student leaders are invited to complete Brilliant Futures™ certification, which includes MiSight® 1 day soft contact lenses for myopia control in children aged 8 to 12 at the initiation of treatment, as well as Paragon CRT® and iSee® ortho-k lenses for myopia management.

This program joins the rebranded Student Contact Lens Leadership Society, to which all North American schools and colleges of optometry likewise name an annual participant.

“Part of CooperVision’s ongoing commitment to advancing the profession includes investing in its future optometrists,” said Justin Kwan, OD, FAAO, Senior Manager, Myopia Management, CooperVision. “Adding a focused myopia management initiative is a natural evolution of our student ambassador programs. In conjunction with their classroom and clinical education, our guidance will better prepare them to be the myopia management advocates of tomorrow.”

The 2021-2022 class of student leaders joined CooperVision at an exclusive welcome reception during the recent American Academy of Optometry Annual Meeting in Boston.

“I’m excited to be part of such a unique network and a nourishing environment. With a deeper knowledge of myopia management, we will be able to educate parents, patients, and peers to truly make a difference,” said Alia Raad, Illinois College of Optometry student and member of the CooperVision Student Myopia Leadership Society inaugural class.

For more information about CooperVision’s Student Myopia Leadership Society and the Student Contact Lens Leadership Society, please visit CooperVision’s Optometry Students & Educators webpage or email

# # #

Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

1 Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit

Media Contact
Hannah Barry, McDougall Communications or +1-585-645-8985